NMN Side Effects & Safety: What Human Studies Actually Found

NMN side effects are generally mild in short human trials, but the long-term safety question is still open. The strongest 2026 pooled evidence is reassuring for common short-term adverse events and liver enzymes; it is much less informative about rare events, multi-year use, pregnancy, active cancer treatment and special populations.

NMN safety at a glance

Question	Evidence-based answer
Common short-term safety	Generally well tolerated in small trials
Serious adverse events	No clear pooled increase in randomized evidence
Liver enzymes	No significant pooled ALT/AST increase
High doses	Short-term trials have tested up to ~2,000 mg/day in specific formulations
Long-term use	Human evidence remains limited; most trials last weeks to months
Pregnancy / breastfeeding	Insufficient human evidence; excluded from EFSA's assessed target population
Cancer treatment	Preclinical evidence is conflicting; oncology supervision is warranted
Product quality	Major issue—independent testing has found label failures and isomer inconsistency

What the 2026 systematic review found

The 2026 systematic review/meta-analysis included 15 randomized trials overall, with 10 contributing to pooled safety analyses. Doses ranged roughly from 250 to 2,000 mg/day and study durations from 14 days to 24 weeks. ^[1]

The pooled data did not show a clear increase in total adverse events, serious adverse events, withdrawals due to adverse events or system-specific adverse events. ALT and AST were not significantly elevated. That is meaningful reassurance for short-term use under trial conditions, not proof of decades-long safety.

What adverse effects have appeared in trials?

Reported symptoms have generally been mild and inconsistent. In a 14-day MIB-626 study, there were no serious adverse events; one participant in the higher-dose group withdrew because of diarrhea, and mild transient liver-enzyme elevations occurred in one NMN participant and one placebo participant. ^[2]

Earlier human safety work also found single-dose oral NMN generally well tolerated in healthy men. ^[3]

High-dose and “overdose” studies

A randomized high-dose safety study included healthy men and women and did not reveal a major short-term toxicity signal. ^[4] A later randomized overdose-intake study similarly focused on safety. ^[5]

A high dose being tolerated for a limited period does not prove that the same dose is optimal or safe for years.

EFSA's 2026 NMN safety opinion

EFSA evaluated a specific chemically synthesized β-NMN novel food intended for adult supplements up to 300 mg/day. The panel concluded that the evaluated material was safe under the proposed conditions. Pregnant and lactating women were excluded. ^[6]

The opinion should not be reworded as “Europe proved all NMN products safe at any dose.”

Does NMN damage the liver?

Current human evidence does not show a consistent hepatotoxicity signal. The 2026 meta-analysis found no significant pooled increase in ALT or AST. ^[7] Longer single-arm exposure in middle-aged Japanese men also did not establish a major liver-safety concern. ^[8]

Supplement-associated liver injury can also depend on contamination, mislabeling, co-ingredients and individual susceptibility.

Kidney disease and acute illness

A randomized study of MIB-626 in hospitalized patients with COVID-19 and acute kidney injury showed that the formulation could raise NAD+ under acute clinical conditions without a clear immediate safety signal. ^[9]

This is not a recommendation for chronic kidney disease self-treatment.

NMN and cancer

NAD+ is required by both normal and cancer cells. In 2026, preclinical pancreatic-cancer research found that NMN could increase cancer-cell survival under chemotherapy stress and reduce treatment effectiveness in mouse models. ^[10]

A different 2026 preclinical study found that high-dose NMN shifted tumor-associated macrophages toward an inflammatory M1-like phenotype and suppressed tumor progression in a mouse mesothelioma model. ^[11]

There is no randomized human trial establishing cancer benefit or long-term cancer risk from NMN. People with active malignancy or receiving chemotherapy should discuss NAD+ precursors with their oncology team. See NMN and cancer.

Children and adolescents

The mainstream human evidence base is overwhelmingly adult. There is no established pediatric anti-aging indication and no comparable randomized long-term safety database.

Drug interactions

Formal drug-interaction trials are sparse. The main issue is the evidence gap in people taking complex medication regimens, especially during chemotherapy or serious chronic disease. See NMN drug interactions.

Product-quality risk may be more practical than molecule toxicity

Independent product testing found large discrepancies between stated and measured NMN content. ^[12] A 2026 isomer-specific analysis identified undeclared or inaccurate composition among commercial supplements. ^[13]

See our NMN purity guide.

How long has NMN been studied in humans?

Most controlled studies are short—commonly several weeks to a few months. The 2026 meta-analysis included trials up to roughly 24 weeks. ^[14]

That is enough to characterize common short-term tolerability reasonably well, not rare or years-long risks.

What “safe” can and cannot mean from the current evidence

Safety evidence has dimensions: common symptoms, laboratory toxicity, serious adverse events, rare events, pregnancy, drug interactions and long-latency outcomes such as cancer. A 12-week RCT can be reassuring for some of these and nearly uninformative for others.

The current NMN literature is strongest for common short-term tolerability in adults. It is much weaker for uncommon events and years-long exposure.

The 2026 pooled safety data

The 2026 meta-analysis included 15 randomized trials overall, with 10 contributing to pooled safety analyses. It found no significant increase in total adverse events, serious adverse events, withdrawals due to adverse events or system-specific adverse events. ALT and AST were also not significantly elevated. ^[15]

This is stronger than saying “no study reported anything bad.” Pooling increases the amount of randomized evidence, although the total participant count remains small relative to drug-safety databases.

How large is the human safety database?

Even dozens of studies can still represent only hundreds of people, often followed for two to twenty-four weeks. A side effect occurring in one person per several thousand users could easily be absent from all trials by chance.

The 2026 broad NAD-augmentation systematic review also noted risk-of-bias concerns across the field and emphasized that tolerability over weeks to months is not equivalent to long-term safety. ^[16]

Who is underrepresented in the evidence?

• Pregnant and breastfeeding people.
• Children and adolescents.
• People with advanced liver or kidney disease.
• People receiving active cancer therapy.
• People using complex polypharmacy regimens.
• Very old or frail adults with multiple comorbidities.
• Long-term users followed for multiple years.

How to monitor tolerability sensibly

New persistent gastrointestinal symptoms, rash, marked headache, unexplained fatigue or clinically significant laboratory changes deserve reassessment rather than automatic attribution to “detox” or NAD restoration. Stop-and-rechallenge decisions should be made cautiously, especially if symptoms are severe.

For medication-specific overlap, see NMN drug interactions.

Related NMN guides

• NMN drug interactions
• NMN and cancer
• NMN dosage evidence
• NMN human safety trials
• product-quality risks
• what happens when you stop NMN

Bottom line

For healthy adults, the short-term NMN safety record is more reassuring than alarming. The honest uncertainty lies beyond the duration and populations actually studied. Product authenticity, cancer context, pregnancy and multi-year exposure deserve more caution than generic marketing pages usually acknowledge.